ZDHHC8

Summary

ZDHHC8 (zDHHC palmitoyltransferase 8, HGNC:18474) is a protein-coding gene on chromosome 22q11.21, encoding Palmitoyltransferase ZDHHC8 (Q9ULC8). Palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates and therefore functions in several unrelated biological processes.

This gene encodes a four transmembrane protein that is a member of the zinc finger DHHC domain-containing protein family. The encoded protein may function as a palmitoyltransferase. Defects in this gene may be associated with a susceptibility to schizophrenia. Alternate splicing of this gene results in multiple transcript variants. A pseudogene of this gene is found on chromosome 22.

Source: NCBI Gene 29801 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 161 total
• MANE Select transcript: NM_013373

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18474
Approved symbol	ZDHHC8
Name	zDHHC palmitoyltransferase 8
Location	22q11.21
Locus type	gene with protein product
Status	Approved
Aliases	ZNF378, KIAA1292, DHHC8
Ensembl gene	ENSG00000099904
Ensembl biotype	protein_coding
OMIM	608784
Entrez	29801

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 12 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000320602, ENST00000334554, ENST00000405930, ENST00000436518, ENST00000468112, ENST00000469212, ENST00000472497, ENST00000924011, ENST00000924012, ENST00000924013, ENST00000924014, ENST00000924015, ENST00000924016, ENST00000924017, ENST00000924018

RefSeq mRNA: 2 — MANE Select: NM_013373 NM_001185024, NM_013373

CCDS: CCDS13776, CCDS54502

Canonical transcript exons

ENST00000334554 — 11 exons

Exon	Start	End
ENSE00001221847	20142756	20143756
ENSE00001221943	20139194	20139315
ENSE00001331437	20140115	20140217
ENSE00001331439	20139720	20139892
ENSE00001705526	20139478	20139635
ENSE00001799604	20145229	20148007
ENSE00001823852	20131804	20132051
ENSE00003459105	20141421	20141530
ENSE00003504610	20141217	20141337
ENSE00003542072	20140617	20140708
ENSE00003595811	20140871	20141012

Expression profiles

Bgee: expression breadth ubiquitous, 214 present calls, max score 96.89.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.1259 / max 58.5077, expressed in 1730 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
191118	5.3896	1676
191117	1.7363	1027

Top tissues by expression

242 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibial nerve	UBERON:0001323	96.89	gold quality
metanephros cortex	UBERON:0010533	95.37	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.79	gold quality
stromal cell of endometrium	CL:0002255	94.50	gold quality
adenohypophysis	UBERON:0002196	93.92	gold quality
right ovary	UBERON:0002118	93.89	gold quality
cerebellar hemisphere	UBERON:0002245	93.87	gold quality
apex of heart	UBERON:0002098	93.86	gold quality
right lobe of thyroid gland	UBERON:0001119	93.81	gold quality
cerebellar cortex	UBERON:0002129	93.76	gold quality
left lobe of thyroid gland	UBERON:0001120	93.68	gold quality
pituitary gland	UBERON:0000007	93.57	gold quality
granulocyte	CL:0000094	93.41	gold quality
right frontal lobe	UBERON:0002810	93.36	gold quality
body of pancreas	UBERON:0001150	93.17	gold quality
body of uterus	UBERON:0009853	93.14	gold quality
left ovary	UBERON:0002119	93.07	gold quality
left adrenal gland cortex	UBERON:0035825	92.97	gold quality
endocervix	UBERON:0000458	92.86	gold quality
right adrenal gland	UBERON:0001233	92.85	gold quality
cerebellum	UBERON:0002037	92.72	gold quality
right lung	UBERON:0002167	92.70	gold quality
right adrenal gland cortex	UBERON:0035827	92.62	gold quality
mucosa of stomach	UBERON:0001199	92.59	gold quality
left uterine tube	UBERON:0001303	92.59	gold quality
adrenal cortex	UBERON:0001235	92.56	gold quality
right coronary artery	UBERON:0001625	92.53	gold quality
left adrenal gland	UBERON:0001234	92.52	gold quality
body of stomach	UBERON:0001161	92.50	gold quality
minor salivary gland	UBERON:0001830	92.43	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

135 targeting ZDHHC8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-106B-5P	99.88	74.72	2795

Literature-anchored findings (GeneRIF, showing 10)

• genotyped three genetic variants within the ZDHHC8 locus and conducted association studies in both population- and family-based samples of the Han Chinese population (PMID:15489219)
• Because our sample size provided quite high power, ZDHHC8 may not play a major role in Japanese schizophrenia and our results did not support the gender-specific effect of this SNP. (PMID:15631889)
• Single nucleotide polymorphism is not associated with chromosome 22 deletion or schizophrenia. (PMID:17728672)
• Data show that palmitoyl acyltransferases DHHC5, DHHC6, and DHHC8 appear to be S-acylated on three cysteine residues within a novel CCX(7-13)C(S/T) motif downstream of a conserved Asp-His-His-Cys cysteine-rich domain. (PMID:19801377)
• The present study provides the first evidence that ZDHHC8 polymorphisms on the 22q11 locus are associated with smooth pursuit eye movement (SPEM)abnormality in a Korean population. (PMID:20468065)
• Consistently negative associations with schizophrenia were found in the rs175174 polymorphism (PMID:20661937)
• increased corpus callosum volume in children with 22q11DS is associated with ZDHHC8 polymorphism. (PMID:22763378)
• These data suggest that ZDHHC8 may play a role in cortical volumes in patients with schizophrenia. (PMID:23403413)
• the association between the COMT Val158Met and ZDHHC8 rs175174 single nucleotide polymorphism and the susceptibility to schizophrenia through a case-control study involving a population from the North Region of Brazil, was investigated. (PMID:28562378)
• AMPKalpha1-mediated ZDHHC8 phosphorylation promotes the palmitoylation of SLC7A11 to facilitate ferroptosis resistance in glioblastoma. (PMID:38211651)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	zdhhc8b	ENSDARG00000018508
mus_musculus	Zdhhc8	ENSMUSG00000060166
rattus_norvegicus	Zdhhc8	ENSRNOG00000021891

Paralogs (1): ZDHHC5 (ENSG00000156599)

Protein

Protein identifiers

Palmitoyltransferase ZDHHC8 — Q9ULC8 (reviewed: Q9ULC8)

Alternative names: Zinc finger DHHC domain-containing protein 8, Zinc finger protein 378

All UniProt accessions (2): Q9ULC8, C9JVM2

UniProt curated annotations — full annotation on UniProt →

Function. Palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates and therefore functions in several unrelated biological processes. Through the palmitoylation of ABCA1 regulates the localization of the transporter to the plasma membrane and thereby regulates its function in cholesterol and phospholipid efflux. Could also pamitoylate the D(2) dopamine receptor DRD2 and regulate its stability and localization to the plasma membrane. Could also play a role in glutamatergic transmission. (Microbial infection) Able to palmitoylate SARS coronavirus-2/SARS-CoV-2 spike protein following its synthesis in the endoplasmic reticulum (ER). In the infected cell, promotes spike biogenesis by protecting it from premature ER degradation, increases half-life and controls the lipid organization of its immediate membrane environment. Once the virus has formed, spike palmitoylation controls fusion with the target cell.

Subcellular location. Golgi apparatus membrane. Mitochondrion membrane.

Tissue specificity. Widely expressed.

Domain organisation. The DHHC domain is required for palmitoyltransferase activity.

Miscellaneous. According to initial studies, defects in ZDHHC8 may contribute to susceptibility to schizophrenia. However, additional studies could not confirm this.

Similarity. Belongs to the DHHC palmitoyltransferase family. ERF2/ZDHHC9 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9ULC8-1	1	yes
Q9ULC8-2	2
Q9ULC8-3	3

RefSeq proteins (2): NP_001171953, NP_037505* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001594	Palmitoyltrfase_DHHC	Domain

Pfam: PF01529

Catalyzed reactions (Rhea), 1 shown:

• L-cysteinyl-[protein] + hexadecanoyl-CoA = S-hexadecanoyl-L-cysteinyl-[protein] + CoA (RHEA:36683)

UniProt features (27 total): modified residue 8, topological domain 5, transmembrane region 4, region of interest 3, compositionally biased region 2, splice variant 2, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9ULC8-F1	57.65	0.26

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 134 (s-palmitoyl cysteine intermediate)

Post-translational modifications (8): 337, 441, 606, 627, 675, 682, 725, 743

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8963896	HDL assembly
R-HSA-9694548	Maturation of spike protein

MSigDB gene sets: 150 (showing top): GGGACCA_MIR133A_MIR133B, CREL_01, GOBP_BEHAVIOR, GOBP_SYNAPSE_ASSEMBLY, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_POSITIVE_REGULATION_OF_CHOLESTEROL_EFFLUX, GOBP_REGULATION_OF_CHOLESTEROL_EFFLUX, GOBP_POSITIVE_REGULATION_OF_STEROL_TRANSPORT, GOBP_MODULATION_OF_PROCESS_OF_ANOTHER_ORGANISM, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_PROTEIN_LIPID_COMPLEX_ASSEMBLY, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GGGTGGRR_PAX4_03

GO Biological Process (7): locomotory behavior (GO:0007626), positive regulation of cholesterol efflux (GO:0010875), peptidyl-L-cysteine S-palmitoylation (GO:0018230), high-density lipoprotein particle assembly (GO:0034380), host-mediated activation of viral process (GO:0044794), regulation of postsynapse assembly (GO:0150052), positive regulation of protein localization to plasma membrane (GO:1903078)

GO Molecular Function (4): palmitoyltransferase activity (GO:0016409), protein-cysteine S-palmitoyltransferase activity (GO:0019706), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (8): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), cytosol (GO:0005829), mitochondrial membrane (GO:0031966), postsynapse (GO:0098794), glutamatergic synapse (GO:0098978), mitochondrion (GO:0005739), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Plasma lipoprotein assembly	1
Translation of Structural Proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	3
cellular anatomical structure	3
intracellular membrane-bounded organelle	2
synapse	2
behavior	1
regulation of cholesterol efflux	1
positive regulation of cholesterol transport	1
cholesterol efflux	1
peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine	1
protein palmitoylation	1
plasma lipoprotein particle assembly	1
host-mediated perturbation of viral process	1
regulation of synapse assembly	1
postsynapse assembly	1
regulation of postsynapse organization	1
protein localization to plasma membrane	1
regulation of protein localization to plasma membrane	1
positive regulation of protein localization to cell periphery	1
positive regulation of protein localization to membrane	1
acyltransferase activity, transferring groups other than amino-acyl groups	1
palmitoyltransferase activity	1
protein-cysteine S-acyltransferase activity	1
catalytic activity	1
transferase activity	1
Golgi apparatus	1
bounding membrane of organelle	1
endomembrane system	1
mitochondrion	1
mitochondrial envelope	1
organelle membrane	1

Protein interactions and networks

STRING

928 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZDHHC8	PRODH	O43272	837
ZDHHC8	PRODH	O43272	824
ZDHHC8	COMT	P21964	811
ZDHHC8	PALM	O75781	795
ZDHHC8	RTN4R	Q9BZR6	746
ZDHHC8	DGCR2	P98153	742
ZDHHC8	MRPL40	Q9NQ50	725
ZDHHC8	TANGO2	Q6ICL3	686
ZDHHC8	ZDHHC13	Q8IUH4	650
ZDHHC8	TAAR6	Q96RI8	645
ZDHHC8	DAOA	P59103	645
ZDHHC8	GNB1L	Q9BYB4	619
ZDHHC8	ZDHHC22	Q8N966	610
ZDHHC8	ZNF74	Q16587	610
ZDHHC8	TRMT2A	Q8IZ69	607

IntAct

11 interactions, top by confidence:

A	B	Type	Score
STX3	NBAS	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
DCAF4	IGLL5	psi-mi:“MI:0914”(association)	0.350
CLDND1	MAN1A2	psi-mi:“MI:0914”(association)	0.350
CLDND1	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
CLDND1	PPL	psi-mi:“MI:0914”(association)	0.350
DNAJA2	ENC1	psi-mi:“MI:0914”(association)	0.350
GDPD5	TMEM120B	psi-mi:“MI:0914”(association)	0.350
P4HA3	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
KRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (39): ZDHHC8 (Affinity Capture-MS), ZDHHC8 (Affinity Capture-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Affinity Capture-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Proximity Label-MS), ZDHHC8 (Proximity Label-MS)

ESM2 similar proteins: A1L3I3, A2A699, A2AEV7, A5PKW4, A8MVW0, D3ZG83, F1MUS9, O14511, O14523, O14559, O35182, O43541, O94983, P46062, P56974, Q02779, Q2THW8, Q2THX0, Q3B8N7, Q3KP66, Q53LP3, Q5BJT1, Q5DTT2, Q5DU25, Q5JU85, Q5RBI7, Q5RD34, Q5VUB5, Q63HR2, Q66H43, Q66L42, Q69YU3, Q69ZH9, Q6PDH0, Q6R6L0, Q7TN12, Q80VC9, Q80Y50, Q80YF9, Q86VZ4

Diamond homologs: A0A0R4IDP3, A2CEX1, A2VEY9, A5WVX9, B3DN87, C8VCL4, E1BLT8, E7F021, E7F587, E7FBS9, E7FH11, E9PTT0, E9QCD3, F1Q7H8, F1QAM1, F1QHM7, F1QX91, F1QXD3, F1R013, F1RE57, J9VJ99, O60069, O74384, O80685, P42836, P59267, P59268, Q04629, Q0VC89, Q10L01, Q2TGJ1, Q2TGJ4, Q2TGK3, Q2THW7, Q2THW8, Q2THW9, Q2THX0, Q2THX1, Q4R690, Q4WZL8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

161 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	139
Likely benign	6
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2166 predictions. Top by Δscore:

Variant	Effect	Δscore
22:20132052:G:GG	donor_gain	1.0000
22:20139461:T:TA	acceptor_gain	1.0000
22:20139468:T:A	acceptor_gain	1.0000
22:20139469:G:A	acceptor_gain	1.0000
22:20139474:GTA:G	acceptor_loss	1.0000
22:20139475:TA:T	acceptor_loss	1.0000
22:20139476:A:AC	acceptor_loss	1.0000
22:20139476:A:AG	acceptor_gain	1.0000
22:20139476:AGCG:A	acceptor_gain	1.0000
22:20139477:G:C	acceptor_loss	1.0000
22:20139477:G:GA	acceptor_gain	1.0000
22:20139477:GC:G	acceptor_gain	1.0000
22:20139477:GCGG:G	acceptor_gain	1.0000
22:20139477:GCGGA:G	acceptor_gain	1.0000
22:20140865:GTGCA:G	acceptor_loss	1.0000
22:20140868:CAG:C	acceptor_loss	1.0000
22:20140869:AGGTA:A	acceptor_loss	1.0000
22:20141010:AAGG:A	donor_loss	1.0000
22:20141012:GGTG:G	donor_loss	1.0000
22:20141014:T:A	donor_loss	1.0000
22:20141215:A:AG	acceptor_gain	1.0000
22:20141216:G:GG	acceptor_gain	1.0000
22:20141420:GA:G	acceptor_gain	1.0000
22:20141420:GAGA:G	acceptor_gain	1.0000
22:20142753:CA:C	acceptor_loss	1.0000
22:20142755:G:A	acceptor_loss	1.0000
22:20132047:TTC:T	donor_gain	0.9900
22:20132051:CG:C	donor_loss	0.9900
22:20132052:GTG:G	donor_loss	0.9900
22:20132053:TGA:T	donor_loss	0.9900

AlphaMissense

4894 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:20139272:C:A	N61K	1.000
22:20139272:C:G	N61K	1.000
22:20139527:G:C	K92N	1.000
22:20139527:G:T	K92N	1.000
22:20139553:T:A	V101D	1.000
22:20139555:C:A	R102S	1.000
22:20139561:A:G	K104E	1.000
22:20139562:A:C	K104T	1.000
22:20139562:A:T	K104M	1.000
22:20139563:G:C	K104N	1.000
22:20139563:G:T	K104N	1.000
22:20139564:T:A	W105R	1.000
22:20139564:T:C	W105R	1.000
22:20139566:G:C	W105C	1.000
22:20139566:G:T	W105C	1.000
22:20139567:T:A	C106S	1.000
22:20139567:T:C	C106R	1.000
22:20139568:G:A	C106Y	1.000
22:20139568:G:C	C106S	1.000
22:20139568:G:T	C106F	1.000
22:20139569:T:G	C106W	1.000
22:20139576:T:A	C109S	1.000
22:20139576:T:C	C109R	1.000
22:20139577:G:A	C109Y	1.000
22:20139577:G:C	C109S	1.000
22:20139577:G:T	C109F	1.000
22:20139578:C:G	C109W	1.000
22:20139583:T:C	F111S	1.000
22:20139585:T:G	Y112D	1.000
22:20139588:C:A	R113S	1.000

dbSNP variants (sampled 300 via entrez): RS1000007222 (22:20132581 C>T), RS1000133423 (22:20130948 A>ATAG), RS1000375308 (22:20146056 G>A,C), RS1000461423 (22:20130665 C>A,T), RS1000542631 (22:20130992 G>A,T), RS1000766921 (22:20136380 C>T), RS1000835940 (22:20137469 G>A,C), RS1000920566 (22:20137416 G>C,T), RS1001325014 (22:20146721 C>G,T), RS1001540181 (22:20131913 G>A), RS1001681918 (22:20131105 G>A), RS1001714676 (22:20139604 C>T), RS1001834509 (22:20142434 CCTATGT>C), RS1001924100 (22:20138494 G>C), RS1002009044 (22:20129862 A>G)

Disease associations

OMIM: gene MIM:608784 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
FR900359	affects phosphorylation	1
dicrotophos	increases expression	1
propionaldehyde	increases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	decreases expression	1
pentanal	increases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Benzo(a)pyrene	decreases methylation	1
Caffeine	affects phosphorylation	1
Cisplatin	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	decreases expression	1
Acrylamide	decreases expression	1
Particulate Matter	increases abundance, increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TZ06	HAP1 ZDHHC8 (-) 1	Cancer cell line	Male
CVCL_TZ07	HAP1 ZDHHC8 (-) 2	Cancer cell line	Male
CVCL_TZ08	HAP1 ZDHHC8 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer